Insights

Read our independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.

Our work is reader-supported. Sign up to our free or paid plans here.

The latest

Pα+ Psychedelic Bulletin #197: Portuguese Health-Related Professions Unite on Psychedelics; Shrooms, Shots, and the Next Surgeon General; Religious Leaders Study Set to Publish

Bridging Promise and Prudence: Portuguese Health-Related Professions Unite to Release First National Guidelines on Psychedelic Therapy • Shrooms, Shots, and the Next Surgeon General: Psychedelics at the Centre of MAGA Infighting • ‘No One Has the Right to Speak for Us’: Religious Leaders Who Participated in Hopkins Study Push Back on Critics As Publication Nears • Manvir Singh Challenges the Stories Westerners Tell About Psychedelics’ Past • Compass Pathways Sets Expectations Ahead of June Readout • and more…

The Interdisciplinary Annotated Psychedelic Research Bibliography of 2024

Psychedelic Alpha’s Medical Advisor, Michael Haichin, compiled a list of over 500 notable psychedelics-related publications from 2024. He then presented it to a group of researchers from varying disciplines, asking for their comments on the papers that they found most intriguing. Here, we present the list along with their comments as our inaugural Interdisciplinary Annotated Psychedelic Research Bibliography.

Spring 2025 Psychedelic Policy Update: Bills Hang in the Balance as Legislative Sessions Wind Down

As spring legislative sessions wind down across the country, some state lawmakers are racing to pass a diverse wave of psychedelic-related bills. From Colorado’s upcoming data collection system to New Mexico’s landmark psilocybin access law and Texas’ flurry of psychedelic-related efforts, here’s a state-by-state look at the major developments… and where the clock may run out.

Dispatch from Breaking Convention 2025: Key Takeaways from Europe’s Largest Psychedelic Summit (Part 2)

From 17–19 April, the UK’s seventh biennial psychedelic conference tackled some of the field’s most urgent questions. In this second instalment, we explore the ethical dilemmas of giving psychedelics to young people, the critical role of therapist selection, how female biology affects drug interactions, the pros and cons of non-hallucinogenic psychoplastogens, and what it really means to integrate psychedelic insights.

Pα+ Psychedelic Bulletin #196: Otsuka Eyes Psychedelic Future in Japan; First Look at Gilgamesh’s Phase 2a Data; ASCP 2025 Preview; VA Sec. Pressed on Psychedelics Plans

Otsuka Eyes Psychedelic Future in Japan with New Infrastructure Drive • ASCP 2025 Preview: Psychedelic Therapies Dominate Clinical Psychopharmacology Agenda • First Look at Gilgamesh’s Phase 2a Data: Psychedelic Candidate Yields Effect Size of ~1.0, But Sparse Details • VA Secretary Pressed for Details on Psychedelics Plans • and more…

The Library

Through our years of reporting we have covered many of the topics we believe to be important to the present and future of the psychedelics space, broadly defined. However, much of this commentary is scattered across Bulletins, deep dives, special reports and year-end reviews.

The Library provides digestible explainers on salient topics across psychedelic drug development, policy and business: from basic explainers such as “what is psychedelic-assisted therapy?” through to more complex matters such as REMS programs and bifurcated scheduling.

It’s exclusively available to our Pα+ subscribers, with new content added regularly.

Pα+ Library: Bifurcated Scheduling

Pα+ Library: we introduce some of the key concepts in the matter of bifurcated scheduling; a process by which an approved drug product may be placed in a different schedule to the substance itself. As we discuss in this piece, this could have significant repercussions for psychedelic research, legality, and even taxes.

Pα+ Library: Psychedelic REMS

Pα+ Library: we sketch out what a psychedelic REMS might look like, highlighting how these programs could have an outsized impact on the post-approval delivery and accessibility of these treatments.

The Psychedelic News Feed Archives

Archived versions of our Psychedelic News Feed.